

Haematologica
HAEMATOL/2018/194522
Version 3

Reduced tyrosine kinase inhibitor dose is predicted to be as effective
as standard dose in chronic myeloid leukemia: A simulation study
based on phase 3 trial data

Artur C. Fassoni, Christoph Baldow, Ingo Roeder, and Ingmar Glauche

Disclosures: The authors declare the following competing interests: IG - travel and research funding from Bristol-Myers Squibb; IR - honorarium, travel and research funding from Bristol-Myers Squibb. ACF and CB declare no competing interests.

Contributions: ACF, CB, IR, IG were involved in conception and design of the study. ACF, IR, IG developed the model concept. ACF derived the analytical solutions and implemented the model. ACF and CB realized the simulations and analyzed the data. ACF, CB, IR, IG were involved in the creation and design of the figures. ACF, CB, IR, IG wrote the manuscript and gave their final approval for its submission.